Why the study?
Does acute myocardial infarction alter platelet sensitivity to platelet activating factor (PAF) and PGI2 ex vivo?
Does acute myocardial infarction alter platelet sensitivity to platelet activating factor (PAF) and PGI2 ex vivo?
Answers are grounded in this paper and cite their sources.
Acute myocardial infarction is associated with a transient increase in platelet sensitivity to PAF and a prolonged decrease in sensitivity to PGI2 inhibition.
Platelets from patients with acute myocardial infarction exhibit an increased sensitivity to the aggregatory effect of PAF, in vitro, the first 48 h after the onset of the symptoms. This sensitivity, expressed as PAF EC50 values, seems to be transient after the 2 day period. Also, a remarkable decreased sensitivity to the inhibitory effect of PGI2 against the aggregation induced by PAF appears to the platelets of those patients the first hours after the onset of the symptoms, and persists for at least 14 days. Treatment of patients by drugs with a known inhibitory effect on platelet aggregation in vivo and in vitro (aspirin, nifedipine, indomethacin), does not influence the increase in platelet sensitivity to PAF, but inhibits the secondary aggregation induced by the released aggregating factors from the PAF activated platelets. The increase in platelet sensitivity to PAF is not unique to the AMI since it is also observed in patients with acute bacterial pneumonia. However, we cannot support the theory that it is a general phenomenon of acute tissue injury since it is general phenomenon of acute tissue injury since it is not observed in patients with acute muscular injury.
No takes yet. Share an insight, caveat, or question.
Tselepis et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: